Published in Cancer Immun on November 02, 2009
γδ T cells in cancer. Nat Rev Immunol (2015) 1.39
Plasticity of γδ T Cells: Impact on the Anti-Tumor Response. Front Immunol (2014) 0.83
The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. Oncoimmunology (2013) 0.81
Complex role of γδ T-cell-derived cytokines and growth factors in cancer. J Interferon Cytokine Res (2012) 0.79
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Basement membrane complexes with biological activity. Biochemistry (1986) 6.79
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
Regulation of cutaneous malignancy by gammadelta T cells. Science (2001) 5.83
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res (1978) 3.54
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol (2008) 3.14
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med (2005) 2.10
Homing and function of human skin gammadelta T cells and NK cells: relevance for tumor surveillance. J Immunol (2006) 2.02
Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med (2003) 1.99
The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol (2000) 1.82
Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol (2005) 1.71
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res (2001) 1.66
Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol (2006) 1.66
Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol (1988) 1.60
The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev (2002) 1.59
Production of interferon-gamma by myeloid cells--fact or fancy? Trends Immunol (2006) 1.55
NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res (2007) 1.50
NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol (2008) 1.46
Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol (2003) 1.40
Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol (2005) 1.39
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol (2006) 1.31
Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol (2009) 1.30
MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol (2007) 1.24
Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants. J Immunol (1990) 1.19
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol (2005) 1.13
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer (2009) 1.11
NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immunol (1996) 1.09
[Immunological aspects of anticancer chemotherapy]. Bull Acad Natl Med (2008) 1.08
In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther (2007) 1.06
Modulation of sensitivity to natural killer cell lysis after in vitro explantation of a mouse lymphoma. J Natl Cancer Inst (1978) 1.01
Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes. J Immunol (1997) 0.98
Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol (2003) 0.93
NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo. Cancer Immunol Immunother (2006) 0.93
Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res (2004) 0.90
Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene. J Exp Med (1993) 0.89
Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol (2008) 0.88
Enhancement of antitumor natural killer cell activation by orally administered Spirulina extract in mice. Cancer Sci (2009) 0.87
Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. Cancer Sci (2008) 0.87
Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol (2005) 0.83
Differential locomotion of long- and short-term IL-2-activated murine natural killer cells in a model matrix environment. Scand J Immunol (2007) 0.80
Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol (2006) 0.79
The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells. Cancer Immun (2008) 0.77
H-2 antigen expression: Loss in vitro, restoration in vivo, and correlation with cell-mediated cytotoxicity in a mouse lymphoma cell line. Immunogenetics (1978) 0.77
Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One (2012) 1.21
Plasmodium falciparum isolates with increased pfmdr1 copy number circulate in West Africa. Antimicrob Agents Chemother (2010) 1.02
T cells infiltrate the brain in murine and human transmissible spongiform encephalopathies. J Virol (2003) 1.00
In vitro and in vivo properties of ellagic acid in malaria treatment. Antimicrob Agents Chemother (2008) 0.94
Mapping and structural dissection of human 20 S proteasome using proteomic approaches. Mol Cell Proteomics (2002) 0.93
Characterization of protein variants and post-translational modifications: ESI-MSn analyses of intact proteins eluted from polyacrylamide gels. Mol Cell Proteomics (2003) 0.84
KBA.62: a useful marker for primary and metastatic melanomas. Hum Pathol (2008) 0.82
Bilateral uterine vessel ligation as a model of intrauterine growth restriction in mice. Reprod Biol Endocrinol (2014) 0.80
Lysosomal serine protease CLN2 regulates tumor necrosis factor-alpha-mediated apoptosis in a Bid-dependent manner. J Biol Chem (2009) 0.80
Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells. Fundam Clin Pharmacol (2004) 0.76
Concepts and ways to amplify the antitumor immune response. Curr Top Microbiol Immunol (2011) 0.76
Characterization and differential expression of a newly identified phosphorylated isoform of the human 20S proteasome beta7 subunit in tumor vs. normal cell lines. Fundam Clin Pharmacol (2009) 0.76
[Bryophytes, a potent source of drugs for tomorrow's medicine?]. Med Sci (Paris) (2008) 0.75
[Molecular genetic methods in anaplastic large cell lymphoma]. Orv Hetil (2003) 0.75
Pharmacological screening of bryophyte extracts that inhibit growth and induce abnormal phenotypes in human HeLa cancer cells. Fundam Clin Pharmacol (2009) 0.75
The use of mass spectrometry to identify antigens from proteasome processing. Methods Enzymol (2005) 0.75